BYSI — BeyondSpring Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1677940 ·
Last close
$0.56
Market Cap
$23.02M
52W High
$2.44
52W Low
$0.42
ADV30
112,084
Next earnings
2026-11-13

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -1,731,000 -849,000 14,606,000 2,697,000 50,631,000
Mar 2026 0 — -2,232,000 -2,159,000 18,406,000 4,036,000 48,760,000
Dec 2025 0 — -2,596,000 -2,137,000 25,933,000 7,786,000 49,923,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,746,000
Investing CF
$-1,893,000
Financing CF
$737,000
CapEx
$-50,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.15
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-411,439,000
Inventory
—
Receivables
—
ST Investments
$3,832,000
EBIT TTM
$-8,349,000
Pretax Income TTM
$-8,014,000
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -8,945,000 -1,006,000 25,933,000 49,923,000 -32,161,000 -19,769,000
Dec 2024 0 -8,754,000 -11,123,000 34,315,000 48,600,000 -32,900,000 -16,443,000
Dec 2023 0 -15,081,000 -21,026,000 24,808,000 48,269,000 -26,805,000 -16,474,000
Dec 2022 1,351,000 -37,239,000 -33,279,000 46,222,000 49,229,000 -5,979,000 -28,151,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-6,685,000
OpCashFlow TTM
—
Assets (Latest)
$14,606,000
Forward EPS
$-0.47

Peers — same industry

TickerNameMarket CapLastDaily %
ETST Earth Science Tech, Inc. $23.17M $0.08 —
CRVO CervoMed Inc. $22.68M $1.50 —
TXMD TherapeuticsMD, Inc. $22.11M $1.91 —
FLNA FILANA THERAPEUTICS, INC. $24.19M $0.48 —
IXHL Incannex Healthcare Inc. $21.83M $1.74 —

News headlines (Yahoo Finance, 1h cache)

BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 22:15 · Yahoo
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances
2026-09-29 14:43 · Yahoo
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
2026-09-29 11:01 · Yahoo
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
2026-08-14 21:15 · Yahoo
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
2026-04-06 10:41 · Yahoo
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
2026-03-30 11:30 · Yahoo
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
2026-04-22 11:00 · Yahoo
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
2026-05-18 11:00 · Yahoo
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
2026-06-04 11:00 · Yahoo
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.